Abstract:Colorectal cancer (CRC) is the leading cause of cancer death; however, targets with broad anti-CRC effects are limited. Sirtuin6 (SIRT6) is a conserved nicotinamide adenine dinucleotide (NAD(+))-dependent deacetylase that is widely pathologically downregulated in CRC, but its pharmacological effect in CRC remains undefined due to the lack of small-molecule SIRT6 activators. We searched for a compound activating SIRT6 and investigated its anti-CRC effect in various models. Methods: We identified an allosteric SIRT6 activator, MDL-811. Its ability to enhance SIRT6 deacetylation at protein and cellular levels was evaluated by Fluor de Lys (FDL) and western blots. We assessed the proliferation of 26 CRC cell lines and patient-derived organoids (PDOs) treated with MDL-811. In vivo efficacy of MDL-811 was evaluated in HCT116 cell line- and patient-derived xenografts as well as a spontaneous CRC model. RNA sequencing and real-time quantitative PCR assays were performed to analyze gene expression changes in MDL-811-treated HCT116 cells. Along with controls in SIRT6-overexpressing HCT116 cells, the SIRT6-mediated histone H3 deacetylation at the Cytochrome P450 family 24 subfamily A member 1 (CYP24A1) gene locus was assessed by chromatin immunoprecipitation (ChIP) in MDL-811-treated HCT116 cells. A combination therapy against CRC based on the downstream gene of SIRT6 activation was evaluated in cells and mouse models. Results: MDL-811 significantly activated SIRT6 histone H3 deacetylation (H3K9Ac, H3K18Ac, and H3K56Ac) in vitro and had broad antiproliferative effects on diverse CRC cell lines and PDOs. More importantly, the in vivo anti-tumor efficacy of MDL-811 was demonstrated across cell line- and patient-derived xenografts and in the APC(min/+) spontaneous CRC model. Mechanically, we identified a new downstream target gene of SIRT6 in CRC, CYP24A1. Based on these findings, a combination drug strategy with MDL-811 to synergistically enhance the anti-CRC effect of vitamin D-3 was validated in vitro and in vivo. Conclusions: Our data provide proof of concept that targeting SIRT6 using a small-molecule activator is an attractive therapeutic strategy for CRC and that MDL-811 could be a promising lead compound for further preclinical and clinical studies of treatments for CRC.

SIRT6, a novel direct transcriptional target of FoxO3a, mediates colon cancer therapy

SIRT6 suppresses colon cancer growth by inducing apoptosis and autophagy through transcriptionally down-regulating Survivin

Overexpression of Sirt6 is a novel biomarker of malignant human colon carcinoma.

Sirtuin 6 inhibits colon cancer progression by modulating PTEN/AKT signaling

MOF-mediated Acetylation of SIRT6 Disrupts SIRT6-FOXA2 Interaction and Represses SIRT6 Tumor-Suppressive Function by Upregulating ZEB2 in NSCLC.

SRSF6-regulated Alternative Splicing That Promotes Tumour Progression Offers a Therapy Target for Colorectal Cancer

Sirtuin 6 is a Negative Regulator of the Anti-Tumor Function of Natural Killer Cells in Murine Inflammatory Colorectal Cancer

Decreased Expression of SIRT6 Promotes Tumor Cell Growth Correlates Closely with Poor Prognosis of Ovarian Cancer.

FOXO3a‑SIRT6 Axis Suppresses Aerobic Glycolysis in Melanoma.

Small-molecule activating SIRT6 elicits therapeutic effects and synergistically promotes anti-tumor activity of vitamin D<sub>3</sub> in colorectal cancer

Inhibition of the overexpressing SIRT6 sensitizes prostate cancer cells to chemotherapeutics

SIRT6 Inhibits Anoikis of Colorectal Cancer Cells by Down-Regulating NDRG1

SIRT1 Suppresses Colorectal Cancer Metastasis by Transcriptional Repression of Mir-15B-5p

SIRT6 Abrogation Promotes Adrenocortical Carcinoma Through Activation of NF-κB Signaling

Expression and clinical value of NAD-dependent deacetylase sirtuin-6 in colorectal cancer patients

SIRT3 promotion reduces resistance to cisplatin in lung cancer by modulating the FOXO3/CDT1 axis

High Levels of SIRT1 Expression Enhance Tumorigenesis and Associate with a Poor Prognosis of Colorectal Carcinoma Patients

High Expression of Cytoplasmic FOXO3 Protein Associated with Poor Prognosis of Rectal Cancer Patients: A Study from Swedish Clinical Trial of Preoperative Radiotherapy to Big Database Analysis

IDDF2024-ABS-0222 Mir-4659A-3p Promotes the Proliferation of Colon Cancer Mediated by 3-Oxoacyl-acp Synthase (OXSM)

FOXQ1-mediated SIRT1 upregulation enhances stemness and radio-resistance of colorectal cancer cells and restores intestinal microbiota function by promoting β-catenin nuclear translocation

Targeted Inhibition of SIRT6 Via Engineered Exosomes Impairs Tumorigenesis and Metastasis in Prostate Cancer